ICU Medical (NASDAQ:ICUI) Hits New 12-Month High – What’s Next?

Shares of ICU Medical, Inc. (NASDAQ:ICUI) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $166.12 and last traded at $167.8310, with a volume of 4195 shares trading hands. The stock had previously closed at $161.46.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ICUI shares. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a report on Monday, June 15th. Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Piper Sandler decreased their target price on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, BTIG Research assumed coverage on shares of ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $172.00.

ICU Medical Stock Performance

The company has a market cap of $4.16 billion, a P/E ratio of 90.02, a PEG ratio of 2.32 and a beta of 0.76. The company has a 50 day moving average price of $146.57 and a 200-day moving average price of $140.00. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company’s revenue was down 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities analysts expect that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Insider Transactions at ICU Medical

In related news, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ICU Medical

Hedge funds have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of ICU Medical in the fourth quarter valued at $58,083,000. Kirr Marbach & Co. LLC IN raised its position in ICU Medical by 18.4% in the first quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock worth $5,702,000 after acquiring an additional 6,863 shares in the last quarter. F m Investments LLC raised its position in ICU Medical by 33.3% in the fourth quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock worth $6,637,000 after acquiring an additional 11,608 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after acquiring an additional 285,648 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in ICU Medical by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after acquiring an additional 89,755 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.